These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7570304)
1. [Is protein p53 an independent prognostic factor in bladder carcinoma?]. Keilholz L Strahlenther Onkol; 1995 Sep; 171(9):543-4. PubMed ID: 7570304 [No Abstract] [Full Text] [Related]
2. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Dekairelle AF; Tombal B; Cosyns JP; Gala JL Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567 [TBL] [Abstract][Full Text] [Related]
3. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
4. [The molecular biology of bladder carcinoma]. Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283 [TBL] [Abstract][Full Text] [Related]
5. New generation of prognostic factors in muscle invasive bladder cancer. Abi-Aad AS Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811 [No Abstract] [Full Text] [Related]
6. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954 [TBL] [Abstract][Full Text] [Related]
8. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659 [TBL] [Abstract][Full Text] [Related]
9. A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. Xu X; Stower MJ; Reid IN; Garner RC; Burns PA Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):611-6. PubMed ID: 9264274 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850 [TBL] [Abstract][Full Text] [Related]
11. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851 [TBL] [Abstract][Full Text] [Related]
12. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266 [TBL] [Abstract][Full Text] [Related]
13. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472 [TBL] [Abstract][Full Text] [Related]
15. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726 [TBL] [Abstract][Full Text] [Related]
16. Bivariate analysis DNA/cytokeratin 7 and flow cytometric measurement of MIB-1 in superficial transitional carcinoma of the bladder (TCC). Methodological aspects and prognostic implications. Leonardi E; Cristofori A; Reich A; Dalla Palma P Eur J Histochem; 1997; 41 Suppl 2():133-4. PubMed ID: 9859817 [No Abstract] [Full Text] [Related]
17. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study]. Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115 [TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Sugano K; Kakizoe T Nat Clin Pract Urol; 2006 Dec; 3(12):642-52. PubMed ID: 17149381 [TBL] [Abstract][Full Text] [Related]
19. [The study of p53 gene mutation in human bladder cancer]. Ding Q; Zhang Y; Sun X Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915 [TBL] [Abstract][Full Text] [Related]
20. [Expression of mutant P53 gene protein product in human bladder carcinoma]. Ye DW Zhonghua Wai Ke Za Zhi; 1993 Aug; 31(8):484-6. PubMed ID: 8112175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]